ATE205536T1 - Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe - Google Patents

Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe

Info

Publication number
ATE205536T1
ATE205536T1 AT93921524T AT93921524T ATE205536T1 AT E205536 T1 ATE205536 T1 AT E205536T1 AT 93921524 T AT93921524 T AT 93921524T AT 93921524 T AT93921524 T AT 93921524T AT E205536 T1 ATE205536 T1 AT E205536T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
mutants
hav
vaccines
Prior art date
Application number
AT93921524T
Other languages
English (en)
Inventor
Ann W Funkhouser
Suzanne U Emerson
Robert H Purcell
Hondt Eric D
Original Assignee
Smithkline Beecham Biolog
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25485989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205536(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog, Us Health filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of ATE205536T1 publication Critical patent/ATE205536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT93921524T 1992-09-18 1993-09-17 Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe ATE205536T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94733892A 1992-09-18 1992-09-18
PCT/US1993/008610 WO1994006446A1 (en) 1992-09-18 1993-09-17 Hepatitis a virus vaccines

Publications (1)

Publication Number Publication Date
ATE205536T1 true ATE205536T1 (de) 2001-09-15

Family

ID=25485989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921524T ATE205536T1 (de) 1992-09-18 1993-09-17 Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe

Country Status (13)

Country Link
US (4) US6180110B1 (de)
EP (1) EP0666751B1 (de)
JP (1) JP3523646B2 (de)
AT (1) ATE205536T1 (de)
AU (1) AU687012B2 (de)
CA (1) CA2144317C (de)
DE (1) DE69330758T2 (de)
DK (1) DK0666751T3 (de)
ES (1) ES2164074T3 (de)
NZ (1) NZ256278A (de)
PT (1) PT666751E (de)
SG (1) SG73999A1 (de)
WO (1) WO1994006446A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP2402465B1 (de) * 2004-07-13 2014-11-19 Gen-Probe Incorporated Verfahren und Kit zur Detektion von Hepatitis-A-Virus-Nukleinsäure
US20100055670A1 (en) * 2005-06-28 2010-03-04 The Government of the US, Represented by the Secretary, Dept. of Health and Human Services Growth of wild-type hepatitis a virus in cell culture
WO2007134250A2 (en) * 2006-05-12 2007-11-22 Goldengate Software, Inc. Method for forming homogeneous from heterogeneous data
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN102174477B (zh) * 2010-12-28 2012-11-21 深圳康泰生物制品股份有限公司 甲型肝炎病毒株sh及其二倍体细胞适应方法
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
KR102277089B1 (ko) 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스
WO2025022020A1 (en) * 2023-07-27 2025-01-30 Universitat De Barcelona Vaccine composition for the treatment or prevention of hepatitis a infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US5516630A (en) 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
GB8800100D0 (en) 1988-01-05 1988-02-10 Almond J W Attenuated viruses
AU662528B2 (en) * 1991-05-08 1995-09-07 Schweiz. Serum- & Impfinstitut Bern New hepatitis A virus strain, method for the isolation of new hepatitis A virus strains and hepatitis A vaccines

Also Published As

Publication number Publication date
DK0666751T3 (da) 2001-11-12
US6423318B1 (en) 2002-07-23
ES2164074T3 (es) 2002-02-16
SG73999A1 (en) 2000-07-18
AU687012B2 (en) 1998-02-19
WO1994006446A1 (en) 1994-03-31
NZ256278A (en) 1996-11-26
DE69330758T2 (de) 2002-07-04
EP0666751A4 (de) 1996-04-24
US6113912A (en) 2000-09-05
US6180110B1 (en) 2001-01-30
JPH08504094A (ja) 1996-05-07
AU4858593A (en) 1994-04-12
EP0666751B1 (de) 2001-09-12
CA2144317A1 (en) 1994-03-31
US6680060B2 (en) 2004-01-20
CA2144317C (en) 2004-08-03
DE69330758D1 (de) 2001-10-18
EP0666751A1 (de) 1995-08-16
JP3523646B2 (ja) 2004-04-26
PT666751E (pt) 2002-01-30
HK1013667A1 (en) 1999-09-03
US20020176869A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
ATE205536T1 (de) Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
FI953731A0 (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
DE69022290D1 (de) Lebende Impfstoffe.
AU7763294A (en) Live in ovo vaccine
ATE70561T1 (de) Verfahren zur kultur des virus der rhinotracheitis des truthahnes und daraus hergestelltes vakzin.
SE9003198L (sv) Fiskvaccin omfattande en virulent, invasiv bakterie
NO950483L (no) Vaksine mot hepatitt-A
US4400472A (en) Novel rabies virus strain and a process for its preparation
CN101757619A (zh) 兽用狂犬病灭活疫苗及其制备方法
ATE270325T1 (de) Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung
NO872919L (no) Fremstilling av pertussis-toksin ved dyrkning av bodella pertussis.
DE69633233D1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
FI98377B (fi) Adherentisti sitoutuneita soluja sisältävä matriisi ja menetelmä virus/virusantigeenin tuottamiseksi
Burden et al. Fasciola hepatica: attempts to immunise rats and mice with metabolic and somatic antigens derived from juvenile flukes
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
Sen et al. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen
Nishibe et al. Induction of SMON-type virus from avian infectious laryngotracheitis virus
Khodzhaev A study of the postvaccination immunity of guinea pigs repeatedly inoculated with a strain of brucella melitensis: Communication II
RU94030087A (ru) Способ получения вакцины против болезни гамборо
BG61384B1 (bg) метод за получаване на жива атенуирана клетъчно-културална ваксина против псевдочума по птиците
NO931821L (no) Hepatitt b vaksinepreparat som omfatter et gallesyresalt
BG100932A (en) Method for the preparation of cellular cultural inactivated vaccine against fowl pest
EP0178928A3 (de) Impfstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution